NIV-话题@MedSci

#NIV#

134篇内容 | 3213人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2007933, encodeId=9d14200e93324, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功, objectType=article, longId=209558, objectId=b719209558c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b719209558c2, replyNumber=0, likeNumber=93, createdTime=2021-09-30, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b719209558c2, moduleTitle=NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b719209558c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007948, encodeId=51f2200e948fd, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=J Immunother Cancer：Nivolumab 联合 ipilimumab治疗晚期罕见妇科肿瘤的疗效和安全性：来自CA209-538临床研究, objectType=article, longId=220657, objectId=8c3622065e52, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c3622065e52, replyNumber=0, likeNumber=63, createdTime=2021-12-13, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c3622065e52, moduleTitle=J Immunother Cancer：Nivolumab 联合 ipilimumab治疗晚期罕见妇科肿瘤的疗效和安全性：来自CA209-538临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c3622065e52)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007960, encodeId=bc9b200e96017, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Oncologist：CheckMate 141亚组分析比较nivolumab（那武利尤单抗）和化疗治疗复发或转移性头颈部鳞状细胞癌（R/M SCCHN）患者的疗效, objectType=article, longId=299383, objectId=8ef92993836d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ef92993836d, replyNumber=0, likeNumber=68, createdTime=2022-08-18, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ef92993836d, moduleTitle=Oncologist：CheckMate 141亚组分析比较nivolumab（那武利尤单抗）和化疗治疗复发或转移性头颈部鳞状细胞癌（R/M SCCHN）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ef92993836d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007945, encodeId=b0c6200e945e3, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Gastric Cancer：纳武利尤单抗（nivolumab）治疗不能切除的晚期或复发的胃/胃食管连接处癌（G/GEJ）的疗效和安全性：来自日本的真实研究数据, objectType=article, longId=217859, objectId=d2a621e8599c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2a621e8599c, replyNumber=0, likeNumber=77, createdTime=2022-06-13, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2a621e8599c, moduleTitle=Gastric Cancer：纳武利尤单抗（nivolumab）治疗不能切除的晚期或复发的胃/胃食管连接处癌（G/GEJ）的疗效和安全性：来自日本的真实研究数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2a621e8599c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007958, encodeId=a0ef200e9585b, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Ann Oncol：不明原发灶肿瘤使用nivolumab（那武利尤单抗）治疗的疗效, objectType=article, longId=295365, objectId=755a295365ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=755a295365ca, replyNumber=0, likeNumber=90, createdTime=2022-05-26, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=755a295365ca, moduleTitle=Ann Oncol：不明原发灶肿瘤使用nivolumab（那武利尤单抗）治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=755a295365ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007938, encodeId=6b48200e938bc, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Gastric Cancer: 纳武利尤单抗（nivolumab）治疗既往治疗进展的晚期胃癌的疗效：ATTRACTION-2研究结果更新, objectType=article, longId=213460, objectId=af9621346022, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af9621346022, replyNumber=0, likeNumber=69, createdTime=2021-07-18, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af9621346022, moduleTitle=Gastric Cancer: 纳武利尤单抗（nivolumab）治疗既往治疗进展的晚期胃癌的疗效：ATTRACTION-2研究结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af9621346022)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007952, encodeId=1e38200e95254, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=SMC 批准针对罕见突变晚期肠癌患者的免疫治疗组合（Nivolumab联合ipilmumab）, objectType=article, longId=292253, objectId=112d2922537c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=112d2922537c, replyNumber=0, likeNumber=76, createdTime=2022-01-13, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=112d2922537c, moduleTitle=SMC 批准针对罕见突变晚期肠癌患者的免疫治疗组合（Nivolumab联合ipilmumab）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=112d2922537c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007956, encodeId=4f8a200e956ab, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=BMC Cancer：多中心数据探索nivolumab治疗经治转移性胃癌患者获益的临床预后因素, objectType=article, longId=293706, objectId=27d9293e064d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27d9293e064d, replyNumber=0, likeNumber=57, createdTime=2022-10-18, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27d9293e064d, moduleTitle=BMC Cancer：多中心数据探索nivolumab治疗经治转移性胃癌患者获益的临床预后因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27d9293e064d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007951, encodeId=0446200e9510b, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Front Oncol：PD-1抑制剂nivolumab（纳武利尤单抗）治疗NSCLC患者的长期生存疗效和血液学标志物的探索, objectType=article, longId=291839, objectId=14f2291839cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14f2291839cd, replyNumber=0, likeNumber=57, createdTime=2022-05-08, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14f2291839cd, moduleTitle=Front Oncol：PD-1抑制剂nivolumab（纳武利尤单抗）治疗NSCLC患者的长期生存疗效和血液学标志物的探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14f2291839cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007937, encodeId=3a0a200e937fe, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性, objectType=article, longId=213326, objectId=17162133260e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17162133260e, replyNumber=0, likeNumber=91, createdTime=2022-04-30, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17162133260e, moduleTitle=Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17162133260e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007950, encodeId=192f200e9503d, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Eur J Cancer：Nivolumab联合多西他赛治疗未经化疗的转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, objectType=article, longId=221438, objectId=433422143891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=433422143891, replyNumber=0, likeNumber=66, createdTime=2022-10-02, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=433422143891, moduleTitle=Eur J Cancer：Nivolumab联合多西他赛治疗未经化疗的转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=433422143891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007944, encodeId=5347200e94482, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=J Immunother Cancer：Ipilimumab+Nivolumab治疗转移性肾细胞癌伴有脑转移患者的疗效, objectType=article, longId=217179, objectId=edee21e17926, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edee21e17926, replyNumber=0, likeNumber=68, createdTime=2021-12-01, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edee21e17926, moduleTitle=J Immunother Cancer：Ipilimumab+Nivolumab治疗转移性肾细胞癌伴有脑转移患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edee21e17926)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007941, encodeId=5fe3200e9410c, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤, objectType=article, longId=214261, objectId=08ac21426112, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08ac21426112, replyNumber=0, likeNumber=85, createdTime=2021-11-05, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08ac21426112, moduleTitle=J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08ac21426112)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007929, encodeId=c2f3200e929d3, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究）, objectType=article, longId=207196, objectId=04c620e196a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04c620e196a7, replyNumber=0, likeNumber=68, createdTime=2021-08-28, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04c620e196a7, moduleTitle=ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04c620e196a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007932, encodeId=4c61200e9322a, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=Prostate：表达AR-V7的转移去势抵抗性前列腺癌中Nivolumab联用ipilimumab以及有无enzalutamide的临床试验, objectType=article, longId=208515, objectId=d0982085157d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0982085157d, replyNumber=0, likeNumber=77, createdTime=2021-07-24, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0982085157d, moduleTitle=Prostate：表达AR-V7的转移去势抵抗性前列腺癌中Nivolumab联用ipilimumab以及有无enzalutamide的临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0982085157d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007936, encodeId=0bc2200e936e2, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=ASCO2021: Nivolumab + Ipilimumab可使晚期NSCLC患者获益（CheckMate-227的4年数据）, objectType=article, longId=212499, objectId=bef02124990d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bef02124990d, replyNumber=0, likeNumber=72, createdTime=2021-08-10, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bef02124990d, moduleTitle=ASCO2021: Nivolumab + Ipilimumab可使晚期NSCLC患者获益（CheckMate-227的4年数据）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bef02124990d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007935, encodeId=384d200e9350a, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=ASCO-2021速递：复发胶质母细胞瘤，Nivolumab联合标准贝伐单抗可使年龄较大的患者受益, objectType=article, longId=212406, objectId=efa62124062e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efa62124062e, replyNumber=0, likeNumber=116, createdTime=2022-01-07, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efa62124062e, moduleTitle=ASCO-2021速递：复发胶质母细胞瘤，Nivolumab联合标准贝伐单抗可使年龄较大的患者受益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efa62124062e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007931, encodeId=1f95200e93100, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=NEJM：Nivolumab联合Cabozantinib治疗晚期肾细胞癌, objectType=article, longId=207911, objectId=9b3720e91188, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b3720e91188, replyNumber=0, likeNumber=88, createdTime=2021-06-10, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b3720e91188, moduleTitle=NEJM：Nivolumab联合Cabozantinib治疗晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b3720e91188)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007943, encodeId=8813200e94348, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=JAMA Oncol：纳武利尤单抗（Nivolumab）联合伊匹木单抗（Ipilimumab）对比纳武利尤单抗治疗既往治疗过的IV期鳞状非小细胞肺癌的疗效：3期临床研究Lung-MAPS1400I, objectType=article, longId=214350, objectId=f3df214350a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3df214350a4, replyNumber=0, likeNumber=181, createdTime=2022-02-13, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3df214350a4, moduleTitle=JAMA Oncol：纳武利尤单抗（Nivolumab）联合伊匹木单抗（Ipilimumab）对比纳武利尤单抗治疗既往治疗过的IV期鳞状非小细胞肺癌的疗效：3期临床研究Lung-MAPS1400I, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3df214350a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2007927, encodeId=4eb0200e927c8, content=<a href='/topic/show?id=601512826f6' target=_blank style='color:#2F92EE;'>#NIV#</a>, objectTitle=JAMA：bamlanivimab- etesevimab联合治疗可降低新冠肺炎患者病毒载量, objectType=article, longId=206250, objectId=56f72062509e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56f72062509e, replyNumber=0, likeNumber=133, createdTime=2021-03-19, rootId=0, userName=tamgche, userId=674961, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56f72062509e, moduleTitle=JAMA：bamlanivimab- etesevimab联合治疗可降低新冠肺炎患者病毒载量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56f72062509e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

NIV

2020-05-29

tamgche (审核中...)

前往app查看评论内容

#NIV#

NEJM：Nivolumab辅助治疗方案用于晚期食管或胃食管交界癌患者III期临床研究获得成功

2021-09-30

tamgche (审核中...)

前往app查看评论内容

#NIV#

J Immunother Cancer：Nivolumab 联合 ipilimumab治疗晚期罕见妇科肿瘤的疗效和安全性：来自CA209-538临床研究

2021-12-13

tamgche (审核中...)

前往app查看评论内容

#NIV#

Oncologist：CheckMate 141亚组分析比较nivolumab（那武利尤单抗）和化疗治疗复发或转移性头颈部鳞状细胞癌（R/M SCCHN）患者的疗效

2022-08-18

tamgche (审核中...)

前往app查看评论内容

#NIV#

Gastric Cancer：纳武利尤单抗（nivolumab）治疗不能切除的晚期或复发的胃/胃食管连接处癌（G/GEJ）的疗效和安全性：来自日本的真实研究数据

2022-06-13

tamgche (审核中...)

前往app查看评论内容

#NIV#

Ann Oncol：不明原发灶肿瘤使用nivolumab（那武利尤单抗）治疗的疗效

2022-05-26

tamgche (审核中...)

前往app查看评论内容

#NIV#

Gastric Cancer: 纳武利尤单抗（nivolumab）治疗既往治疗进展的晚期胃癌的疗效：ATTRACTION-2研究结果更新

2021-07-18

tamgche (审核中...)

前往app查看评论内容

#NIV#

SMC 批准针对罕见突变晚期肠癌患者的免疫治疗组合（Nivolumab联合ipilmumab）

2022-01-13

tamgche (审核中...)

前往app查看评论内容

#NIV#

BMC Cancer：多中心数据探索nivolumab治疗经治转移性胃癌患者获益的临床预后因素

2022-10-18

tamgche (审核中...)

前往app查看评论内容

#NIV#

Front Oncol：PD-1抑制剂nivolumab（纳武利尤单抗）治疗NSCLC患者的长期生存疗效和血液学标志物的探索

2022-05-08

tamgche (审核中...)

前往app查看评论内容

#NIV#

Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性

2022-04-30

tamgche (审核中...)

前往app查看评论内容

#NIV#

Eur J Cancer：Nivolumab联合多西他赛治疗未经化疗的转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性

2022-10-02

tamgche (审核中...)

前往app查看评论内容

#NIV#

J Immunother Cancer：Ipilimumab+Nivolumab治疗转移性肾细胞癌伴有脑转移患者的疗效

2021-12-01

tamgche (审核中...)

前往app查看评论内容

#NIV#

J Clin Oncol：Bempegaldesleukin 联合纳武利尤单抗（Nivolumab）一线治疗转移性黑色素瘤

2021-11-05

tamgche (审核中...)

前往app查看评论内容

#NIV#

ASCO GU 2021: Nivolumab联合Cabozantinib与舒尼替尼在晚期肾细胞癌中效果对比（CheckMate 9ER研究）

2021-08-28

tamgche (审核中...)

前往app查看评论内容

#NIV#

Prostate：表达AR-V7的转移去势抵抗性前列腺癌中Nivolumab联用ipilimumab以及有无enzalutamide的临床试验

2021-07-24

tamgche (审核中...)

前往app查看评论内容

#NIV#

ASCO2021: Nivolumab + Ipilimumab可使晚期NSCLC患者获益（CheckMate-227的4年数据）

2021-08-10

tamgche (审核中...)

前往app查看评论内容

#NIV#

ASCO-2021速递：复发胶质母细胞瘤，Nivolumab联合标准贝伐单抗可使年龄较大的患者受益

2022-01-07

tamgche (审核中...)

前往app查看评论内容

#NIV#

NEJM：Nivolumab联合Cabozantinib治疗晚期肾细胞癌

2021-06-10

tamgche (审核中...)

前往app查看评论内容

#NIV#

JAMA Oncol：纳武利尤单抗（Nivolumab）联合伊匹木单抗（Ipilimumab）对比纳武利尤单抗治疗既往治疗过的IV期鳞状非小细胞肺癌的疗效：3期临床研究Lung-MAPS1400I

2022-02-13

tamgche (审核中...)

前往app查看评论内容

#NIV#

JAMA：bamlanivimab- etesevimab联合治疗可降低新冠肺炎患者病毒载量

2021-03-19

科室
- - 订阅+
  - 更多科室
工具
服务